Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Guggenheim Downgrades Immunogen to Neutral, Raises Price Target to $31

Author: Benzinga Newsdesk | December 01, 2023 05:38am

Guggenheim analyst Michael Schmidt downgrades Immunogen (NASDAQ:IMGN) from Buy to Neutral and raises the price target from $25 to $31.

Posted In: IMGN